163 related articles for article (PubMed ID: 18682943)
1. In vivo anti-melanoma efficacy of allo-restricted CTLs specific for melanoma expanded by artificial antigen-presenting cells.
Lu XL; Jiang XB; Liu RE; Zhang SM; Liang ZH
Cancer Immunol Immunother; 2009 Apr; 58(4):629-38. PubMed ID: 18682943
[TBL] [Abstract][Full Text] [Related]
2. Adoptive transfer of pTRP2-specific CTLs expanding by bead-based artificial antigen-presenting cells mediates anti-melanoma response.
Lu X; Jiang X; Liu R; Zhao H; Liang Z
Cancer Lett; 2008 Nov; 271(1):129-39. PubMed ID: 18621475
[TBL] [Abstract][Full Text] [Related]
3. Artificial antigen-presenting cells plus IL-15 and IL-21 efficiently induce melanoma-specific cytotoxic CD8+ CD28+ T lymphocyte responses.
Yu X; He J; Mongkhoune S; Peng Y; Xie Y; Su J; Zhou SF; Xie XX; Luo GR; Fang Y; Li X; Li X; Zhou N; Zhao YX; Lu XL
Asian Pac J Trop Med; 2013 Jun; 6(6):467-72. PubMed ID: 23711708
[TBL] [Abstract][Full Text] [Related]
4. Generation of allo-restricted cytotoxic T lymphocytes against malignant glioma by artificial antigen-presenting cells.
Lu XL; Jiang XB; Liu RE; Zhang FC; Zhao HY
Cancer Lett; 2007 Oct; 256(1):128-35. PubMed ID: 17719173
[TBL] [Abstract][Full Text] [Related]
5. Raising allo-restricted cytotoxic T lymphocytes by co-culture of murine splenocytes with autologous macrophage bearing the peptide/allo-major histococompatibility complex.
Chen X; Yan Y; Lu S; Weng X; Liang Z; Li J; Zhong M; Tang J; Xiao W; Sun W; Shen G; Wu X
Hum Immunol; 2009 Feb; 70(2):79-84. PubMed ID: 19100802
[TBL] [Abstract][Full Text] [Related]
6. HLA Tetramer Based Artificial Antigen-Presenting Cells Efficiently Stimulate CTLs Specific for Malignant Glioma.
Jiang X; Lu X; Liu R; Zhang F; Zhao H
Clin Cancer Res; 2007 Dec; 13(24):7329-34. PubMed ID: 18094414
[TBL] [Abstract][Full Text] [Related]
7. Induction of cytotoxic T-lymphocytes specific for malignant glioma by HLA dimer-based artificial antigen-presenting cells.
Xiaobing J; Xiaoling L; Ruen L; Fangcheng Z; Hongyang Z
Cancer Biother Radiopharm; 2007 Dec; 22(6):826-35. PubMed ID: 18158774
[TBL] [Abstract][Full Text] [Related]
8. Efficient amplification of melanoma-specific CD8+ T cells using artificial antigen presenting complex.
Chang J
Exp Mol Med; 2006 Dec; 38(6):591-8. PubMed ID: 17202834
[TBL] [Abstract][Full Text] [Related]
9. Generation of Pure Highly Functional Human Anti-Tumor Specific Cytotoxic T Lymphocytes With Stem Cell-Like Memory Features for Melanoma Immunotherapy.
Hamieh M; Chatillon JF; Dupel E; Bayeux F; Fauquembergue E; Maby P; Drouet A; Duval-Modeste AB; Adriouch S; Boyer O; Latouche JB
Front Immunol; 2021; 12():674276. PubMed ID: 34566953
[TBL] [Abstract][Full Text] [Related]
10. An Artificial Antigen-Presenting Cell Delivering 11 Immune Molecules Expands Tumor Antigen-Specific CTLs in
Zhang L; Song S; Jin X; Wan X; Shahzad KA; Pei W; Zhao C; Shen C
Cancer Immunol Res; 2019 Jul; 7(7):1188-1201. PubMed ID: 31113806
[TBL] [Abstract][Full Text] [Related]
11. PEGylated and CD47-conjugated nanoellipsoidal artificial antigen-presenting cells minimize phagocytosis and augment anti-tumor T-cell responses.
Song S; Jin X; Zhang L; Zhao C; Ding Y; Ang Q; Khaidav O; Shen C
Int J Nanomedicine; 2019; 14():2465-2483. PubMed ID: 31040669
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic minor histocompatibility antigen HA-1-specific CD8+ effector memory T cells: artificial APCs pave the way for clinical application by potent primary in vitro induction.
Schilbach K; Kerst G; Walter S; Eyrich M; Wernet D; Handgretinger R; Xie W; Rammensee HG; Müller I; Bühring HJ; Niethammer D
Blood; 2005 Jul; 106(1):144-9. PubMed ID: 15731181
[TBL] [Abstract][Full Text] [Related]
13. 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.
Zhang H; Snyder KM; Suhoski MM; Maus MV; Kapoor V; June CH; Mackall CL
J Immunol; 2007 Oct; 179(7):4910-8. PubMed ID: 17878391
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells.
Oelke M; Maus MV; Didiano D; June CH; Mackensen A; Schneck JP
Nat Med; 2003 May; 9(5):619-24. PubMed ID: 12704385
[TBL] [Abstract][Full Text] [Related]
15. Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas.
Crowley NJ; Slingluff CL; Darrow TL; Seigler HF
Cancer Res; 1990 Feb; 50(3):492-8. PubMed ID: 2404572
[TBL] [Abstract][Full Text] [Related]
16. Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells.
Ichikawa J; Yoshida T; Isser A; Laino AS; Vassallo M; Woods D; Kim S; Oelke M; Jones K; Schneck JP; Weber JS
Clin Cancer Res; 2020 Jul; 26(13):3384-3396. PubMed ID: 32241816
[TBL] [Abstract][Full Text] [Related]
17. Folate-modified Chitosan Nanoparticles Containing the IP-10 Gene Enhance Melanoma-specific Cytotoxic CD8(+)CD28(+) T Lymphocyte Responses.
He J; Duan S; Yu X; Qian Z; Zhou S; Zhang Z; Huang X; Huang Y; Su J; Lai C; Meng J; Zhou N; Lu X; Zhao Y
Theranostics; 2016; 6(5):752-61. PubMed ID: 27022421
[TBL] [Abstract][Full Text] [Related]
18. Generation of melanoma-specific cytotoxic T lymphocytes for allogeneic immunotherapy.
Nolte A; Scheffold C; Slotty J; Huenefeld C; Schultze JL; Grabbe S; Berdel WE; Kienast J
J Immunother; 2003; 26(3):257-69. PubMed ID: 12806279
[TBL] [Abstract][Full Text] [Related]
19. Paracrine release of IL-2 and anti-CTLA-4 enhances the ability of artificial polymer antigen-presenting cells to expand antigen-specific T cells and inhibit tumor growth in a mouse model.
Zhang L; Wang L; Shahzad KA; Xu T; Wan X; Pei W; Shen C
Cancer Immunol Immunother; 2017 Sep; 66(9):1229-1241. PubMed ID: 28501941
[TBL] [Abstract][Full Text] [Related]
20. Direct Toll-Like Receptor 8 signaling increases the functional avidity of human CD8+ T lymphocytes generated for adoptive T cell therapy strategies.
Chatillon JF; Hamieh M; Bayeux F; Abasq C; Fauquembergue E; Drouet A; Guisier F; Latouche JB; Musette P
Immun Inflamm Dis; 2015 Mar; 3(1):1-13. PubMed ID: 25866635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
